Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jan 24, 2020; 11(1): 20-30
Published online Jan 24, 2020. doi: 10.5306/wjco.v11.i1.20
Published online Jan 24, 2020. doi: 10.5306/wjco.v11.i1.20
Ipsilateral breast tumor recurrence in early stage breast cancer patients treated with breast conserving surgery and adjuvant radiation therapy: Concordance of biomarkers and tumor location from primary tumor to in-breast tumor recurrence
Juhi M Purswani, Fauzia Shaikh, S Peter Wu, Nelly Huppert, Carmen A Perez, Naamit K Gerber, Department of Radiation Oncology, New York University School of Medicine, New York, NY 10016, United States
Jennifer Chun Kim, Freya Schnabel, Department of Surgery, New York University School of Medicine, New York, NY 10016, United States
Author contributions: Purswani JM and Gerber NK designed the research; Purswani JM, Gerber NK and Wu SP performed the research; Purswani JM and Wu SP analyzed the data; Purswani JM, Gerber NK, Kim JC, Schnabel F, Huppert N and Perez CA wrote the paper.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of New York University School of Medicine on December 13, 2017. This is an exempt study, annual renewal is not required.
Informed consent statement: Patients were not required to give informed consent to the research study. The analysis used anonymized clinical data obtained after each subject agreed to treatment with written consent.
Conflict-of-interest statement: There are no financial disclosures, conflicts of interest, and/or acknowledgments for all the authors.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Naamit K Gerber, MD, Assistant Professor, Department of Radiation Oncology, New York University School of Medicine, 160 E. 34th Street, New York, NY 10016, United States. naamit.gerber@nyumc.org
Received: March 23, 2019
Peer-review started: March 26, 2019
First decision: August 2, 2015
Revised: October 21, 2015
Accepted: November 6, 2019
Article in press: November 6, 2019
Published online: January 24, 2020
Processing time: 277 Days and 22.2 Hours
Peer-review started: March 26, 2019
First decision: August 2, 2015
Revised: October 21, 2015
Accepted: November 6, 2019
Article in press: November 6, 2019
Published online: January 24, 2020
Processing time: 277 Days and 22.2 Hours
Core Tip
Core tip: Distinguishing a new primary breast tumor from a true ipsilateral breast tumor recurrence (IBTR) based on clinical features alone is challenging among patients with early stage breast cancer treated with breast conserving surgery and adjuvant radiotherapy. Our aim was to describe primary and recurrent tumor characteristics in patients who experienced an IBTR. We retrospectively analyzed patients with isolated IBTR. Estrogen/progesterone receptor status from primary tumor to IBTR was highly associated, as was the concordance between the quadrant of primary to IBTR. Tumor size greater than 1.5 cm and use of adjuvant endocrine therapy decreased the risk of IBTR.